Literature DB >> 15482632

The many faces of fatigue in major depressive disorder.

Koen Demyttenaere1, Jürgen De Fruyt, Stephen M Stahl.   

Abstract

Fatigue is a common complaint in the community and medical care settings. Different studies show a high comorbidity between fatigue and depressive disorder. Furthermore, fatigue is an important somatic symptom of depressive disorder and one of the main depressive presentations in primary-care medicine. Fatigue shows a slow response to antidepressant treatment and psychotherapy. Improved work performance is strongly correlated to improvement in energy. However, the assessment and treatment of fatigue in depressive disorder remains understudied. Different definitions of fatigue in depressive disorder are applied in DSM-IV and ICD-10, and depression rating scales all show a different coverage of this core depressive symptom, thereby hampering scientific research. Serotonin, norepinephrine, dopamine and histamine mediate symptoms of fatigue in depressive disorder. Although few data address the effect of antidepressants or augmentation strategies on fatigue-related symptoms, there is a pharmacological rationale for using antidepressant monotherapies, such as venlafaxine, bupropion, sertraline, fluoxetine, or augmentation of first-line treatment with stimulants or modafinil.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15482632     DOI: 10.1017/S1461145704004729

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  88 in total

1.  Fatigue as a residual symptom of depression.

Authors:  Steven D Targum; Maurizio Fava
Journal:  Innov Clin Neurosci       Date:  2011-10

Review 2.  The behavioral pharmacology of effort-related choice behavior: dopamine, adenosine and beyond.

Authors:  John D Salamone; Merce Correa; Eric J Nunes; Patrick A Randall; Marta Pardo
Journal:  J Exp Anal Behav       Date:  2012-01       Impact factor: 2.468

Review 3.  Effort-related functions of nucleus accumbens dopamine and associated forebrain circuits.

Authors:  J D Salamone; M Correa; A Farrar; S M Mingote
Journal:  Psychopharmacology (Berl)       Date:  2007-01-16       Impact factor: 4.530

4.  Differential actions of adenosine A1 and A2A antagonists on the effort-related effects of dopamine D2 antagonism.

Authors:  John D Salamone; Andrew M Farrar; Laura Font; Vatsal Patel; Devra E Schlar; Eric J Nunes; Lyndsey E Collins; Thomas N Sager
Journal:  Behav Brain Res       Date:  2009-03-03       Impact factor: 3.332

5.  The adenosine A2A antagonist MSX-3 reverses the effort-related effects of dopamine blockade: differential interaction with D1 and D2 family antagonists.

Authors:  Lila T Worden; Mona Shahriari; Andrew M Farrar; Kelly S Sink; Jörg Hockemeyer; Christa E Müller; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2008-12-02       Impact factor: 4.530

Review 6.  Dopamine/adenosine interactions involved in effort-related aspects of food motivation.

Authors:  John D Salamone; Merce Correa
Journal:  Appetite       Date:  2009-07-25       Impact factor: 3.868

Review 7.  The role of the central noradrenergic system in behavioral inhibition.

Authors:  Eric A Stone; Yan Lin; Yasmeen Sarfraz; David Quartermain
Journal:  Brain Res Rev       Date:  2011-03-05

8.  Antidepressant response to aripiprazole augmentation associated with enhanced FDOPA utilization in striatum: a preliminary PET study.

Authors:  Charles R Conway; John T Chibnall; Paul Cumming; Mark A Mintun; Marie Anne I Gebara; Dana C Perantie; Joseph L Price; Martha E Cornell; Jonathan E McConathy; Sunil Gangwani; Yvette I Sheline
Journal:  Psychiatry Res       Date:  2014-01-14       Impact factor: 3.222

9.  Cortical abnormalities and association with symptom dimensions across the depressive spectrum.

Authors:  Marc S Lener; Prantik Kundu; Edmund Wong; Kaitlin E Dewilde; Cheuk Y Tang; Priti Balchandani; James W Murrough
Journal:  J Affect Disord       Date:  2015-10-30       Impact factor: 4.839

10.  Dopamine, behavioral economics, and effort.

Authors:  John D Salamone; Merce Correa; Andrew M Farrar; Eric J Nunes; Marta Pardo
Journal:  Front Behav Neurosci       Date:  2009-09-07       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.